TY  - JOUR
AU  - Bozorgmehr, Farastuk
AU  - Chung, Inn
AU  - Fischer, Jürgen R
AU  - Bischof, Marc
AU  - Atmaca, Akin
AU  - Wetzel, Sophie
AU  - Faehling, Martin
AU  - Bottke, Dirk
AU  - Wermke, Martin
AU  - Troost, Esther G C
AU  - Kropf-Sanchen, Cornelia
AU  - Wiegel, Thomas
AU  - Schmidt, Bernd
AU  - Stupavsky, Andrej
AU  - Engel-Riedel, Walburga
AU  - Hammer-Hellmig, Michaela
AU  - Reinmuth, Niels
AU  - Manapov, Farkhad
AU  - Grohe, Christian
AU  - Krempien, Robert
AU  - Schumann, Christian
AU  - Sterzing, Florian
AU  - Reck, Martin
AU  - Würschmidt, Florian
AU  - Fleckenstein, Jochen
AU  - Petroff, Alev
AU  - Henschke, Sven
AU  - Behnisch, Rouven
AU  - Cvetkovic, Jelena
AU  - Brückner, Lena
AU  - Schwab, Constantin
AU  - Stenzinger, Albrecht
AU  - Götze, Thorsten
AU  - Kopp, Christina
AU  - Schröder, Helge
AU  - Debus, Jürgen
AU  - Christopoulos, Petros
AU  - Thomas, Michael
AU  - Rieken, Stefan
TI  - Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).
JO  - Clinical & experimental metastasis
VL  - 42
IS  - 5
SN  - 0262-0898
CY  - Dordrecht
PB  - Springer Science + Business Media B.V.
M1  - DKFZ-2025-01541
SP  - 42
PY  - 2025
AB  - Introduction of immune checkpoint inhibitors (ICI) has improved overall survival (OS) for advanced non-small cell lung cancer (NSCLC). However, responses differ greatly amongst patients. Additional radiotherapy (RT) may promote tumor-specific immunity and synergize with ICI to improve tumor control. The multicenter phase II FORCE trial evaluated safety and efficacy of nivolumab with additional palliative radiotherapy (5 × 4 Gy) as clinically indicated in pre-treated metastatic non-squamous NSCLC (group A, n = 41), including pretreated patients without an indication for radiotherapy in a parallel cohort as real-world controls (group B, n = 60). With an objective response rate (ORR) of 8.3
KW  - Humans
KW  - Carcinoma, Non-Small-Cell Lung: therapy
KW  - Carcinoma, Non-Small-Cell Lung: pathology
KW  - Carcinoma, Non-Small-Cell Lung: mortality
KW  - Carcinoma, Non-Small-Cell Lung: drug therapy
KW  - Male
KW  - Female
KW  - Lung Neoplasms: pathology
KW  - Lung Neoplasms: therapy
KW  - Lung Neoplasms: mortality
KW  - Lung Neoplasms: drug therapy
KW  - Aged
KW  - Middle Aged
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Palliative Care: methods
KW  - Nivolumab: therapeutic use
KW  - Programmed Cell Death 1 Receptor: antagonists & inhibitors
KW  - Aged, 80 and over
KW  - Adult
KW  - Immunotherapy (Other)
KW  - Nivolumab (Other)
KW  - Non-small cell lung cancer (Other)
KW  - Palliative radiotherapy (Other)
KW  - Radioimmunotherapy (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
KW  - Nivolumab (NLM Chemicals)
KW  - Programmed Cell Death 1 Receptor (NLM Chemicals)
KW  - PDCD1 protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40702361
C2  - pmc:PMC12287132
DO  - DOI:10.1007/s10585-025-10358-x
UR  - https://inrepo02.dkfz.de/record/303122
ER  -